Navidea Biopharmaceuticals (NAVB) Announces the Presentation of Manocept Data At Keystone Symposia For Molecular Cell Biology Of Macrophages In Human Disease
2/13/2014 8:11:52 AM
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced data utilizing compounds from the Company’s Manocept™ platform in models of rheumatoid arthritis are being presented by Thomas Rosol, DVM, PhD, DACVP from The Ohio State University at a Keystone Symposia on Molecular Cell Biology of Macrophages in Human Disease held, February 9-14 in Santa Fe, NM.
Help employers find you! Check out all the jobs and post your resume.
comments powered by